Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5.1% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 5.1% during mid-day trading on Monday . The stock traded as high as $6.95 and last traded at $6.81. 1,852,293 shares changed hands during trading, a decline of 67% from the average session volume of 5,697,418 shares. The stock had previously closed at $6.48.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. KeyCorp cut their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Down 1.9 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The stock has a fifty day moving average price of $6.70 and a two-hundred day moving average price of $7.67. The company has a market cap of $1.89 billion, a P/E ratio of -4.16 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same period in the previous year, the business earned ($0.38) earnings per share. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Christopher Gibson sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $6.35, for a total transaction of $95,250.00. Following the completion of the transaction, the chief financial officer now owns 1,340,968 shares in the company, valued at approximately $8,515,146.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 201,682 shares of company stock worth $1,322,013 in the last 90 days. Insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently bought and sold shares of the company. Perceptive Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the 2nd quarter worth about $5,769,000. Capstone Investment Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $161,000. Benjamin F. Edwards & Company Inc. raised its position in shares of Recursion Pharmaceuticals by 6,439.6% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after purchasing an additional 167,302 shares during the period. Scientech Research LLC bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth $1,052,000. Finally, Ghisallo Capital Management LLC bought a new position in Recursion Pharmaceuticals in the 2nd quarter worth about $8,250,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.